PHASE Scientific International Limited completed a US$34 million Series A funding round, the largest in Asia's diagnostic technology sector since 2019, to accelerate R&D and commercialization of its proprietary PHASIFY™ urine-based diagnostic technology for early detection of cancers, women's health issues, and infectious diseases.
Related articles
Press ReleaseMay 8, 2026
West Enclave Merger Corp. Announces the Separate Trading of its Ordinary Shares and Rights, Commencing May 13, 2026
May 8, 2026
Press ReleaseMay 8, 2026
Shreya Acquisition Group Announces Closing of $110 Million Initial Public Offering (Including Partial Exercise of Over-Allotment Option)
May 8, 2026
Press ReleaseMay 8, 2026
Con Edison Announces $2 Billion At-The-Market (ATM) Equity Offering Program
May 8, 2026
← Back to all articles
Generated by Yeal